Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution

PLoS Computational Biology

Volumn 12, Issue 2, 2016, Pages

  Bozic, Ivana ^a,b   Gerold, Jeffrey M ^a   Nowak, Martin A ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; POPULATION STATISTICS; STOCHASTIC SYSTEMS;

CANCER CELLS; CELL-BE; CELL/B.E; CELL/BE; EVOLUTIONARY HISTORY; METASTATIC LESIONS; MOLECULAR CLOCK; REPRODUCTIVE RATES; STOCHASTICS; TUMOR LESIONS;

CANCER CELLS;

ARTICLE; CANCER CELL; CELL POPULATION; CLONAL MUTATION; DISEASE COURSE; EXOME; GENE MUTATION; HUMAN; METASTASIS; MUTATION RATE; NEOPLASM; PHYLOGENETIC TREE; PHYLOGENY; PRIMARY TUMOR; PROBABILITY; SUBCLONAL MUTATION; TUMOR GROWTH; BIOLOGICAL MODEL; BIOLOGY; GENETICS; MOLECULAR EVOLUTION; MUTATION; PROCEDURES; STATISTICAL MODEL;

COMPUTATIONAL BIOLOGY; EVOLUTION, MOLECULAR; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; MUTATION; NEOPLASMS;

EID: 84959564974     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004731     Document Type: Article

References (54)

1. Tomasetti C, Vogelstein B, Parmigiani G, Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA. 2013;110(6): 1999–2004. doi: 10.1073/pnas.122106811023345422
2. Frank SA, Nowak MA, Developmental predisposition to cancer. Nature. 2003;422: 494.
3. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ, Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res. 2004;64: 3414–3427. doi: 10.1158/0008-5472.CAN-03-324915150093
4. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescue VE, et al. Genetic progression and the waiting time to cancer. PLOS Comput Biol. 2007;3(11): e225. doi: 10.1371/journal.pcbi.003022517997597
5. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010;107(43): 18545–18550. doi: 10.1073/pnas.101097810720876136
6. Bozic I, Nowak MA, Unwanted evolution. Science. 2013;342(6161): 938–939. doi: 10.1126/science.124788724264980
7. Nowak MA, Michor F, Iwasa Y, The linear process of somatic evolution. Proc Natl Acad Sci USA. 2003;100: 14966–14969. doi: 10.1073/pnas.253541910014657359
8. Nowak MA, Evolutionary Dynamics. Harvard University Press, Cambridge, MA; 2006.
9. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr.Kinzler KW, Cancer genome landscapes. Science. 2013;339(6127): 1546–1558. doi: 10.1126/science.123512223539594
10. Rodriguez-Brenes IA, Komarova NL, Wodarz D, Tumor growth dynamics: insights into somatic evolutionary processes. Trends Ecol Evol. 2013;28: 597–604. doi: 10.1016/j.tree.2013.05.02023816268
11. Wodarz D, Komarova NL, Dynamics of Cancer: Mathematical Foundations of Oncology. World Scientific, New Jersey; 2014.
12. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood2014;124(3): 453–462. doi: 10.1182/blood-2014-04-56793324891321
13. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160: 48–61. doi: 10.1016/j.cell.2014.12.03325594174
14. Bozic I, Nowak MA, Timing and heterogeneity of mutations associated with drug-resistance in metastatic cancers. Proc Natl Acad Sci USA. 2014;111(45): 15964–15968. doi: 10.1073/pnas.141207511125349424
15. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319): 1114–1117. doi: 10.1038/nature0951520981102
16. Jones S, Chen W, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105(11): 4283–4288. doi: 10.1073/pnas.071234510518337506
17. Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, et al. A Big Bang model of human colorectal tumor growth. Nat Genet. 2015;47(3): 209–216. doi: 10.1038/ng.321425665006
18. Luria SE, Delbrück M, Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943;28: 491–511. 17247100
19. Dewanji A, Luebeck EG, Moolgavkar SH, A generalized Luria-Delbrück model. Math Biosci. 2005;197(2): 140–152. doi: 10.1016/j.mbs.2005.07.00316137718
20. Coldman AJ, Goldie JH, A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Biosci. 1983;65: 291–307. doi: 10.1016/0025-5564(83)90066-4
21. Iwasa Y, Nowak MA, Michor F, Evolution of resistance during clonal expansion. Genetics. 2006;172: 2557–2566. doi: 10.1534/genetics.105.04979116636113
22. Komarova NL, Wu L, Baldi P, The fixed-size Luria-Delbruck model with a nonzero death rate. Math Biosci. 2007;210(1): 253–290. doi: 10.1016/j.mbs.2007.04.00717583754
23. Kessler DA, Levine H, Large population solution of the stochastic Luria-Delbrück evolution model. Proc Natl Acad Sci USA. 2013;110: 11682–11687. doi: 10.1073/pnas.130966711023818583
24. Kessler DA, Levine H, Scaling solution in the large population limit of the general asymmetric stochastic Luria-Delbrück evolution process. J Stat Phys. 2015;158(4): 783–805. doi: 10.1007/s10955-014-1143-3
25. Keller P, Antal T, Mutant number distribution in an exponentially growing population. J Stat Mech Theor Exp. 2015;2015(1): P01011. doi: 10.1088/1742-5468/2015/01/P01011
26. Athreya KB, Ney PE, Branching Processes. Springer, New York; 1972.
27. Kimmel M, Axelrod DE, Braching Processes in Biology. Springer, New York; 2015.
28. Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F, Cancer evolution: mathematical models and computational inference. Syst Biol. 2015;64(1): e1–e25. doi: 10.1093/sysbio/syu08125293804
29. Diaz LA, JrWilliams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486: 537–540.
30. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, et al. Reliable detection of subclonal single-nucleotide variants in tumor cell populations. Nat Commun. 2012;3: 811. doi: 10.1038/ncomms181422549840
31. Gillespie DT, Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;81(25): 2340–2361. doi: 10.1021/j100540a008
32. The Cancer genome Atlas NetworkComprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature. 2012;487(7407): 330–337. doi: 10.1038/nature1125222810696
33. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45: 1134–1140. doi: 10.1038/ng.276024071852
34. Sottoriva A, Graham T, A pan-cancer signature of neutral tumor evolution; 2015. Preprint. Available: bioRxiv.
35. Luebeck EG, Curtius K, Jeon J, Hazelton W, Impact of tumor progression on cancer incidence curves. Cancer Res. 2013;73(3): 1086–1096. doi: 10.1158/0008-5472.CAN-12-219823054397
36. Curtius K, Hazelton W, Jeon J, Luebeck EG, A Multiscale Model Evaluates Screening for Neoplasia in Barrett’s Esophagus. PloS Comput Bio. 2015;11(5): e1004272. doi: 10.1371/journal.pcbi.1004272
37. Kerr JFR, Searle J, A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol. 1972;107(1): 41–44. doi: 10.1002/path.17110701075069401
38. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152(4): 714–726. doi: 10.1016/j.cell.2013.01.01923415222
39. Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F, Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia. PLOS ONE. 2011;6: e27682. doi: 10.1371/journal.pone.002768222140458
40. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. 2013;2: e00747. http://dx.doi.org/10.7554/eLife.00747doi: 10.7554/eLife.0074723805382
41. Griffiths RC, Pakes AG, An infinite-alleles version of the simple branching process. Adv Appl Prob. 1988;20(3): 489–524. doi: 10.2307/1427033
42. Wu X, Kimmel M, Modeling Neutral Evolution Using an Infinite-Allele Markov Branching Process. Int J Stoch Anal. 2013; 2013: 963831.
43. Durrett R, Population genetics of neutral mutations in exponentially growing cancer cell populations. Ann Appl Probab. 2013;23(1): 230–250. doi: 10.1214/11-AAP82423471293
44. Harwood J, Tachibana A, Davis R, Bhattacharyya NP, Meuth M, High rate of multilocus deletion in a human tumor cell line. Hum Mol Genet. 1993;2(2): 165–171. doi: 10.1093/hmg/2.2.1658499904
45. Nowak MA, Komarova NL, Sengupta A, Jallepalli PF, Shih IM, Vogelstein B, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci USA. 2002;99: 16226–16231. doi: 10.1073/pnas.20261739912446840
46. Komarova NL, Lengauer C, Vogelstein B, Nowak MA, Dynamics of genetic instability in sporadic and familial colorectal cancer. Cancer Biol Ther. 2002;1: 685–692. doi: 10.4161/cbt.32112642695
47. Durrett R, Foo J, Leder K, Mayberry J, Michor F, Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 2011;188(2): 461–477. doi: 10.1534/genetics.110.12572421406679
48. Reiter JG, Bozic I, Allen B, Chatterjee K, Nowak MA, The effect of one additional driver mutation on tumor progression. Evol Appl. 2013;6(1): 34–45. doi: 10.1111/eva.1202023396615
49. Durrett R, Moseley S, Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol2010;77(1): 42–48. doi: 10.1016/j.tpb.2009.10.00819896491
50. Bozic I, Allen B, Nowak MA, Dynamics of targeted cancer therapy. Trends Mol Med. 2012;18: 311–316. doi: 10.1016/j.molmed.2012.04.00622595628
51. Rodrigues-Brenes IA, Wodarz D, Komarova NL, Characterizing inhibited tumor growth in stem-cell-driven non-spatial cancers. Math Biosci. 2015; 270: 135–141. doi: 10.1016/j.mbs.2015.08.009
52. Potten CS, Booth C, Hargreaves D, The small intestine as a model for evaluating adult tissue stem cell drug targets. Cell Proliferat. 2003;36(3): 115–129. doi: 10.1046/j.1365-2184.2003.00264.x
53. Bernard S, Belair J, Mackey MC, Oscillations in cyclical neutropenia: new evidence based on mathematical modeling. J Theor Biol. 2003;228(1): 143. doi: 10.1016/j.jtbi.2004.01.006
54. Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, A spatial model predicts that dispersal and cell turnover limit intratumor heterogeneity. Nature2015;525, 261–264. doi: 10.1038/nature1497126308893